← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
L2 Diagnostics, Llc
New Haven, CT
$56,681,499
Total funding
83
Grants
Funding over time
peak $4.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$56,681,499 · 83
By mechanism
R41$14,945,142 · 37
R44$11,059,392 · 8
U01$10,637,392 · 2
R42$9,626,499 · 7
R43$7,063,919 · 24
N44$1,996,011 · 1
Investigators at L2 Diagnostics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy$1,996,011
N44 · FY2017 · CA
Recombinant Subunit West Nile Virus Vaccine Development$1,673,045
U01 · FY2005 · AI
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway$1,655,184
U01 · FY2012 · AI
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway$1,619,778
U01 · FY2011 · AI
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway$1,605,387
U01 · FY2013 · AI
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway$1,151,358
U01 · FY2009 · AI
Recombinant Subunit West Nile Virus Vaccine Development$992,079
U01 · FY2006 · AI
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway$989,745
U01 · FY2010 · AI
A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1$988,360
R42 · FY2022 · AI
A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1$980,219
R42 · FY2024 · AI
A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1$979,482
R42 · FY2023 · AI
Recombinant Subunit West Nile Virus Vaccine Development$950,816
U01 · FY2004 · AI
A serologic assay to measure successful Lyme borreliosis antibiotic therapy$883,404
R44 · FY2014 · AI
A serologic assay to measure successful Lyme borreliosis antibiotic therapy$879,662
R44 · FY2016 · AI
A serologic assay to measure successful Lyme borreliosis antibiotic therapy$879,662
R44 · FY2015 · AI
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens$829,432
R44 · FY2014 · AI
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens$825,690
R44 · FY2015 · AI
Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy$780,982
R44 · FY2017 · AR
Bio-monitoring Methylene Diphenyl Diisocyanate (MDI) exposure and body burden$736,600
R42 · FY2011 · ES
Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy$694,516
R44 · FY2016 · AR